Advanced NSCLC

Oncology·MeSH: Lung Neoplasms

7 drugs in development·6 companies·2 clinical trials

Drug Pipeline by Phase

Phase 2(3)

Drug	Company
adagrasib oral dose of	Mirati Therapeutics, Inc. (MRTX)
ct053ptsa	SUNSHINE BIOPHARMA INC. (SBFM)
JS207 injection +JS004 injection	Merus N.V. (MRUS)

Preclinical(1)

Drug	Company
primary immune response	Biodesix Inc. (BDSX)

Phase 4(3)

Drug	Company
alectinib	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
alectinib	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
JS207 injection	Merus N.V. (MRUS)

BioSniper tracks 7 drugs in development for Advanced NSCLC across 6 companies.

There are 2 clinical trials targeting Advanced NSCLC tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.